Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) updated its U.S. portfolio, highlighting the science-based 18 Series nutraceutical line. Four launched products with projections—Noor18, Liv18, Fort18, Cur18—target annualized U.S. revenue of over $22.7M and implied gross profit of about $17.0M at ~75% gross margins.
The 18 Series remains early stage; the company aims for 18 products and views the U.S. platform as a long-term revenue and profitability pillar.
Cosmos Health (NASDAQ:COSM) announced that its subsidiary Cana Laboratories received new contract manufacturing orders from Nassington and Verisfield totaling 253,657 units.
The contracts cover multiple medicines and pharmaceutical products, supporting Cosmos Health's vertically integrated, diversified manufacturing business and reinforcing relationships with established pharmaceutical partners.
Cosmos Health (NASDAQ:COSM) reported over $1.5 million in combined annualized sales for its C-Scrub and C-Sept antiseptic brands across the UK and Greece, with gross margins above 70%.
The company targets 2028 revenue of $7.4 million and gross profit of $5.3 million via EU expansion and animal healthcare.
Cosmos Health (NASDAQ:COSM) signed a non-binding LOI to acquire 100% of Doc Pharma S.A., a GMP pharmaceutical manufacturer. Doc Pharma has an approximately $24 million asset base, $6.7 million three-year average annual revenue and $3.2 million gross profit.
The deal is expected to be accretive, enhancing assets, margins, profitability, cash flow, production capacity, product portfolio, and R&D. It is a related-party transaction, subject to independent review, PCAOB audit, shareholder approval, final due diligence, and may not close.
Cosmos Health (NASDAQ:COSM) received a further 180-day Nasdaq extension, until December 7, 2026, to regain compliance with the $1.00 minimum bid price requirement.
The company meets all other Nasdaq Capital Market listing criteria and aims to restore compliance by executing its business strategy, treating any potential reverse stock split as a last resort.
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield.
Cana will produce 1.3 million units annually of VASCLOR GEST progesterone 400mg vaginal pessaries, totaling 3.9 million units, expanding its contract manufacturing customer base and capabilities in women's health and reproductive medicine.
Cosmos Health (NASDAQ:COSM) reported record FY2025 revenue of $65.3M, up 20% year-over-year, and an 83% gross profit increase to $7.9M with 12.1% margin. Q1 2026 revenue reached $17.9M, up 31%.
The company expects FY2026 revenue above $90M (~38% growth) and is targeting over $200M revenue and $44.2M adjusted EBITDA by 2029. Balance sheet metrics improved, non-core assets of about $20M were identified, and U.S. operations are underway with projected annualized revenue above $20M at roughly 75% gross margins within 12–18 months.
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories has launched a state-of-the-art capsule production line and signed a new five-year contract manufacturing agreement with Provident Pharmaceuticals.
Cana will produce 385,000 units of CERTORUN (77,000 annually), supporting high-margin, recurring revenue and a diversified product portfolio, according to Cosmos Health.
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm, enhancing its proprietary IP portfolio and product development pipeline.
Cana is pursuing national and regional patent protection and expanding nanotechnology-based platforms, leveraging its European GMP-licensed, EMA-certified manufacturing to develop pharmaceutical, nutraceutical, OTC, and specialized healthcare products, aligned with Cosmos Health’s vertical integration strategy.
Cosmos Health (NASDAQ:COSM) launched Oliv18 in the U.S., expanding its science-based 18 Series nutraceuticals into cardiovascular and antioxidant categories. Oliv18 is a USDA and EU organic-certified, 100% solvent-free whole olive polyphenol supplement sourced from Moroccan Saharan olive fruit and leaf.
A 250 mg daily dose, described as a clinically studied serving size, delivers about 11 teaspoons equivalent of extra virgin olive oil polyphenols and meets EFSA’s 5 mg/day hydroxytyrosol minimum for LDL oxidation protection. Oliv18 targets global cardiovascular and antioxidant markets projected to exceed $33 billion by 2035.